Monitor for continuity in financial strategy and investor communications during the transition. The planned succession suggests stability, but investors should assess Matthews' integration and future guidance.
Price Chart
Executive Summary
Eton Pharmaceuticals announced the appointment of Judith Matthews as CFO, effective June 1, 2026, succeeding James Gruber, who will transition to a six-month consulting role. The move represents a planned leadership succession.
Key Facts
- Judith Matthews appointed CFO effective June 1, 2026
- James Gruber to step down as CFO but remain through May 31, 2026, then enter six-month consulting agreement
- Matthews' compensation includes $440,000 annual base salary, 45% target bonus, and 37,000 stock options vesting over four years
- Matthews previously served as CFO at Iterum Therapeutics and VP of Finance at Durata Therapeutics
- No family relationships or reportable transactions between Matthews and the company
Financial Impact
Minimal immediate financial impact. Long-term impact depends on Matthews' execution. Stock option grant of 37,000 shares represents minor dilution.
Risk Factors
- Execution risk during leadership transition
- Potential for strategic shift under new CFO
- Dilution from equity grant
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-012488 |
| Exhibit: ex_945240.htm | 0001437749-26-012488 |
| Document: 0001437749-26-012488-index-headers.html | 0001437749-26-012488 |
| Document: 0001437749-26-012488-index.html | 0001437749-26-012488 |
| Document: 0001437749-26-012488.txt | 0001437749-26-012488 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers